Novo Nordisk A/S
CSE:NOVO B

Watchlist Manager
Novo Nordisk A/S Logo
Novo Nordisk A/S
CSE:NOVO B
Watchlist
Price: 899.1 DKK -1.66%
Updated: Aug 14, 2024
Have any thoughts about
Novo Nordisk A/S?
Write Note

Intrinsic Value

Novo Nordisk A/S is a global healthcare company, which engages in the the discovery, development, manufacturing and marketing of pharmaceutical products. [ Read More ]

The intrinsic value of one NOVO B stock under the Base Case scenario is hidden DKK. Compared to the current market price of 899.1 DKK, Novo Nordisk A/S is hidden .

Key Points:
NOVO B Intrinsic Value
HIDDEN
Unlock
Worst Case
Base Case
Best Case

Valuation Backtest
Novo Nordisk A/S

Backtest Intrinsic Value
Dive into the past to invest in the future

Run backtest to discover the historical profit from buying and selling NOVO B based on its intrinsic value.

Analyze the historical link between intrinsic value and market price to make more informed investment decisions.

Run Backtest
Settings
Valuation Methods
Buy/Sell Thresholds
Buy When:
%
Sell When:
%
B
S
Run Backtest
How does it work?

Fundamental Analysis

AI Assistant
AI Assistant
Ask me anything about Novo Nordisk A/S

Provide an overview of the primary business activities
of Novo Nordisk A/S.

What unique competitive advantages
does Novo Nordisk A/S hold over its rivals?

What risks and challenges
does Novo Nordisk A/S face in the near future?

Summarize the latest earnings call
of Novo Nordisk A/S.

What significant events have occurred
in Novo Nordisk A/S over the past months?

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Novo Nordisk A/S.

Provide P/S
for Novo Nordisk A/S.

Provide P/E
for Novo Nordisk A/S.

Provide P/OCF
for Novo Nordisk A/S.

Provide P/FCFE
for Novo Nordisk A/S.

Provide P/B
for Novo Nordisk A/S.

Provide EV/S
for Novo Nordisk A/S.

Provide EV/GP
for Novo Nordisk A/S.

Provide EV/EBITDA
for Novo Nordisk A/S.

Provide EV/EBIT
for Novo Nordisk A/S.

Provide EV/OCF
for Novo Nordisk A/S.

Provide EV/FCFF
for Novo Nordisk A/S.

Provide EV/IC
for Novo Nordisk A/S.

Show me price targets
for Novo Nordisk A/S made by professional analysts.

What are the Revenue projections
for Novo Nordisk A/S?

How accurate were the past Revenue estimates
for Novo Nordisk A/S?

What are the Net Income projections
for Novo Nordisk A/S?

How accurate were the past Net Income estimates
for Novo Nordisk A/S?

What are the EPS projections
for Novo Nordisk A/S?

How accurate were the past EPS estimates
for Novo Nordisk A/S?

What are the EBIT projections
for Novo Nordisk A/S?

How accurate were the past EBIT estimates
for Novo Nordisk A/S?

Compare the revenue forecasts
for Novo Nordisk A/S with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Novo Nordisk A/S and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Novo Nordisk A/S against its competitors.

Analyze the profit margins
(gross, operating, and net) of Novo Nordisk A/S compared to its peers.

Compare the P/E ratios
of Novo Nordisk A/S against its peers.

Discuss the investment returns and shareholder value creation
comparing Novo Nordisk A/S with its peers.

Analyze the financial leverage
of Novo Nordisk A/S compared to its main competitors.

Show all profitability ratios
for Novo Nordisk A/S.

Provide ROE
for Novo Nordisk A/S.

Provide ROA
for Novo Nordisk A/S.

Provide ROIC
for Novo Nordisk A/S.

Provide ROCE
for Novo Nordisk A/S.

Provide Gross Margin
for Novo Nordisk A/S.

Provide Operating Margin
for Novo Nordisk A/S.

Provide Net Margin
for Novo Nordisk A/S.

Provide FCF Margin
for Novo Nordisk A/S.

Show all solvency ratios
for Novo Nordisk A/S.

Provide D/E Ratio
for Novo Nordisk A/S.

Provide D/A Ratio
for Novo Nordisk A/S.

Provide Interest Coverage Ratio
for Novo Nordisk A/S.

Provide Altman Z-Score Ratio
for Novo Nordisk A/S.

Provide Quick Ratio
for Novo Nordisk A/S.

Provide Current Ratio
for Novo Nordisk A/S.

Provide Cash Ratio
for Novo Nordisk A/S.

What is the historical Revenue growth
over the last 5 years for Novo Nordisk A/S?

What is the historical Net Income growth
over the last 5 years for Novo Nordisk A/S?

What is the current Free Cash Flow
of Novo Nordisk A/S?

Discuss the annual earnings per share (EPS)
trend over the past five years for Novo Nordisk A/S.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Novo Nordisk A/S

Current Assets 116.4B
Cash & Short-Term Investments 9.3B
Receivables 71.8B
Other Current Assets 35.4B
Non-Current Assets 182.5B
Long-Term Investments 1.7B
PP&E 98.2B
Intangibles 59.6B
Other Non-Current Assets 23B
Current Liabilities 165.6B
Accounts Payable 13B
Other Current Liabilities 152.6B
Non-Current Liabilities 34.4B
Long-Term Debt 16.8B
Other Non-Current Liabilities 17.6B
Efficiency

Earnings Waterfall
Novo Nordisk A/S

Revenue
244.2B DKK
Cost of Revenue
-37.5B DKK
Gross Profit
206.7B DKK
Operating Expenses
-97.3B DKK
Operating Income
109.4B DKK
Other Expenses
-20.1B DKK
Net Income
89.3B DKK

Free Cash Flow Analysis
Novo Nordisk A/S

Last Value
3-Years Average
FCF Margin
Conversion Rate
Earnings Calls

In Q1 2024, Novo Nordisk achieved a 24% increase in sales and a 30% rise in operating profit. The company raised its full-year outlook, driven by solid demand for its diabetes and obesity treatments, particularly GLP-1 therapies. North American sales grew by 35%, while international operations saw an 11% increase. Notably, obesity care sales soared by 42%, led by Wegovy. The company also reported a 32% rise in carbon emissions due to higher capital expenditure. Commitments to sustainability included a higher percentage of women in senior leadership roles and significant R&D milestones, such as the approval of the Wegovy label expansion in the U.S.

What is Earnings Call?
Fundamental Scores

NOVO B Profitability Score
Profitability Due Diligence

Novo Nordisk A/S's profitability score is hidden . The higher the profitability score, the more profitable the company is.

Exceptional 3-Year Average ROE
Positive Free Cash Flow
Exceptional 3-Year Average ROIC
Positive Gross Profit
hidden
Profitability
Score

Novo Nordisk A/S's profitability score is hidden . The higher the profitability score, the more profitable the company is.

NOVO B Solvency Score
Solvency Due Diligence

Novo Nordisk A/S's solvency score is hidden . The higher the solvency score, the more solvent the company is.

High Interest Coverage
High Altman Z-Score
Low D/E
Long-Term Solvency
hidden
Solvency
Score

Novo Nordisk A/S's solvency score is hidden . The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

NOVO B Price Targets Summary
Novo Nordisk A/S

Wall Street analysts forecast NOVO B stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for NOVO B is 963.15 DKK .

Lowest
Price Target
Not Available
Average
Price Target
963.15 DKK
7% Upside
Highest
Price Target
Not Available
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for NOVO B?

Click here to dive deeper.

Shareholder Yield

Current shareholder yield for NOVO B is hidden .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
HIDDEN
Unlock
Dividend Yield
Lowest
Average
Highest
Buyback Yield
HIDDEN
Debt Paydown Yield
HIDDEN
Want to learn more about NOVO B dividends, buybacks, and debt paydown yield?

Click here to dive deeper.

NOVO B Price
Novo Nordisk A/S

1M 1M
-8%
6M 6M
+6%
1Y 1Y
+46%
3Y 3Y
+192%
5Y 5Y
+517%
10Y 10Y
+964%
Annual Price Range
899.1
52w Low
616.3852
52w High
1 028
Price Metrics
Average Annual Return 35.12%
Standard Deviation of Annual Returns 25.69%
Max Drawdown -19%
Shares Statistics
Market Capitalization 4T DKK
Shares Outstanding 4 461 908 793
Percentage of Shares Shorted
N/A

Competitive Landscape

NOVO B News

Other Videos

Company Profile

Novo Nordisk A/S Logo
Novo Nordisk A/S

Country

Denmark

Industry

Pharmaceuticals

Market Cap

4T DKK

Dividend Yield

1.05%

Description

Novo Nordisk A/S is a global healthcare company, which engages in the the discovery, development, manufacturing and marketing of pharmaceutical products. The firm is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The firm operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The firm's diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs. The firm's biopharmaceuticals segment covers the therapy areas of hemophilia care, growth hormone therapy and hormone replacement therapy. The firm also offers Saxenda product to treat obesity. The company offers a range of products, including NovoLog/NovoRapid; NovoLog Mix/NovoMix; Prandin/NovoNorm; NovoSeven; Norditropin, and Vagifem. As of December 31, 2016, it marketed its products in over 180 countries. Its regional structure consists of two commercial units: North America and International Operations.

Contact

Bagsvaerd
Novo Alle 1
+4544448888.0
www.novonordisk.com

IPO

1974-05-17

Employees

47 792

Officers

President, CEO & Member of Management Board
Mr. Lars Fruergaard Jorgensen
Executive VP, CFO & Member of the Management Board
Mr. Karsten Munk Knudsen
Executive VP of Product Supply, Quality & IT and Member of the Management Board
Mr. Henrik Ehlers Wulff
Executive VP of Commercial Strategy & Corporate Affairs and Member of the Management Board
Ms. Camilla Sylvest
Executive VP of Development & Member of the Management Board
Dr. Martin Holst Lange
EVP of Research & Early Development, Chief Scientific Officer & Member of the Management Board
Dr. Marcus Schindler Ph.D.
Show More
Executive VP of International Operations & Member of the Management Board
Mr. Maziar Mike Doustdar
Executive VP of North America Operations & Member of Management Board
Mr. Douglas J. Langa
Executive VP, Head of Rare Disease & Member of Management Board
Mr. Ludovic Helfgott
Executive VP of Global People & Organisation and Member of Management Board
Ms. Tania Sabroe
Show Less

See Also

Discover More
What is the Intrinsic Value of one NOVO B stock?

The intrinsic value of one NOVO B stock under the Base Case scenario is hidden DKK.

Is NOVO B stock undervalued or overvalued?

Compared to the current market price of 899.1 DKK, Novo Nordisk A/S is hidden .

Back to Top